Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$39.26 USD

39.26
549,252

-0.14 (-0.36%)

Updated Sep 20, 2024 03:59 PM ET

After-Market: $39.27 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

SurModics (SRDX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

SurModics (SRDX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Down -5.46% in 4 Weeks, Here's Why SurModics (SRDX) Looks Ripe for a Turnaround

by Zacks Equity Research

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

SurModics (SRDX) Loses -6.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's What Key Metrics Tell Us About SurModics (SRDX) Q3 Earnings

by Zacks Equity Research

Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

SurModics (SRDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 12.90% and 0.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Chewy, Pitney Bowes, 3M in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Surmodics (SRDX) Inks Group Purchasing Agreement With Premier

by Zacks Equity Research

Surmodics (SRDX) inks the group purchasing agreement for its thrombectomy products with Premier.

Why Is Perrigo (PRGO) Down 15.1% Since Last Earnings Report?

by Zacks Equity Research

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is SurModics (SRDX) Up 21.9% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

by Zacks Equity Research

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

by Zacks Equity Research

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

SurModics (SRDX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Indrajit Bandyopadhyay headshot

What's in Store for These 4 Medical Device Stocks in Q1 Earnings?

by Indrajit Bandyopadhyay

Here is a sneak peek into how the four medical device stocks, COR, GKOS, ARAY and SRDX, might fare in their quarterly results slated to be release tomorrow.

SurModics (SRDX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 119.44% and 11.02%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Can the 4 Medical Device Stocks Hit Targets This Earnings Season?

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neogen (NEOG) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Neogen (NEOG) delivered earnings and revenue surprises of -14.29% and 0.49%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?

New Strong Buy Stocks for April 9th

by Zacks Equity Research

SRDX, X, TELNY, INSP and MTAL have been added to the Zacks Rank #1 (Strong Buy) List on April 9, 2023.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.

SurModics (SRDX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SurModics (SRDX) Reports Break-Even Earnings for Q1

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 100% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

Medical Device Stocks' Earnings on Feb 1: RVTY, CAH & More

by Debanjana Dey

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how CAH, RVTY, CNMD, SRDX and BDX are placed ahead of their earnings releases.